Analysts Are Bullish on These Technology Stocks: Life360 Shs Chess Depository Interests Repr 3 Sh (LIFX), Adyen (ADYYF)
There's a lot to be optimistic about in the Technology sector as 2 analysts just weighed in on Life360 Shs Chess Depository Interests Repr 3 Sh (LIFX – Research Report) and Adyen (ADYYF – Research Report) with bullish sentiments.
Confident Investing Starts Here:
Life360 Shs Chess Depository Interests Repr 3 Sh (LIFX)
Ord Minnett analyst Lindsay Bettiol maintained a Buy rating on Life360 Shs Chess Depository Interests Repr 3 Sh today and set a price target of A$27.10. The company's shares closed last Tuesday at $20.14.
Bettiol has an average return of 70.8% when recommending Life360 Shs Chess Depository Interests Repr 3 Sh.
According to TipRanks.com, Bettiol is ranked #4793 out of 9554 analysts.
Currently, the analyst consensus on Life360 Shs Chess Depository Interests Repr 3 Sh is a Strong Buy with an average price target of $17.85, implying an 11.6% upside from current levels. In a report issued on May 2, Goldman Sachs also maintained a Buy rating on the stock with a A$27.00 price target.
Adyen (ADYYF)
In a report issued on May 12, Sebastien Sztabowicz from Kepler Capital maintained a Buy rating on Adyen, with a price target of EUR2000.00. The company's shares closed last Tuesday at $1888.52, close to its 52-week high of $1958.15.
According to TipRanks.com, Sztabowicz is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -4.8% and a 42.5% success rate. Sztabowicz covers the Technology sector, focusing on stocks such as Telefonaktiebolaget LM Ericsson, Infineon Technologies AG, and ams-OSRAM.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Adyen with a $2178.48 average price target, a 15.3% upside from current levels. In a report issued on April 28, Jefferies also maintained a Buy rating on the stock with a EUR2152.00 price target.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
a day ago
- Business Insider
Positive Report for Betmakers Technology Group (TPBTF) from Ord Minnett
Betmakers Technology Group (TPBTF – Research Report) received a Buy rating and a A$0.23 price target from Ord Minnett analyst Lindsay Bettiol today. The company's shares closed last Friday at $0.08. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Bettiol covers the Technology sector, focusing on stocks such as Qoria, Life360 Shs Chess Depository Interests Repr 3 Sh, and Technology One Limited. According to TipRanks, Bettiol has an average return of 6.1% and a 42.19% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Betmakers Technology Group with a $0.13 average price target, a 58.54% upside from current levels. In a report released on May 23, Canaccord Genuity also reiterated a Buy rating on the stock with a A$0.20 price target.
Business Insider
3 days ago
- Business Insider
Analysts Offer Insights on Industrial Goods Companies: Performance Shipping (PSHG) and Sterling Construction (STRL)
There's a lot to be optimistic about in the Industrial Goods sector as 2 analysts just weighed in on Performance Shipping (PSHG – Research Report) and Sterling Construction (STRL – Research Report) with bullish sentiments. Confident Investing Starts Here: Performance Shipping (PSHG) In a report issued on May 30, Tate Sullivan from Maxim Group reiterated a Buy rating on Performance Shipping, with a price target of $5.00. The company's shares closed last Tuesday at $1.60, close to its 52-week low of $1.48. According to Sullivan 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -9.9% and a 38.7% success rate. Sullivan covers the Industrial Goods sector, focusing on stocks such as United Maritime Corp., Seanergy Maritime, and BWX Technologies. The the analyst consensus on Performance Shipping is currently a Hold rating. William Blair analyst Louie DiPalma maintained a Buy rating on Sterling Construction today. The company's shares closed last Tuesday at $194.23, close to its 52-week high of $206.07. According to DiPalma has 0 stars on 0-5 stars ranking scale with an average return of -11.7% and a 60.6% success rate. DiPalma covers the Technology sector, focusing on stocks such as Palantir Technologies, Science Applications, and BigBearai Holdings. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sterling Construction with a $205.00 average price target.
Business Insider
3 days ago
- Business Insider
Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS) and Arcus Biosciences (RCUS)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Exact Sciences (EXAS – Research Report) and Arcus Biosciences (RCUS – Research Report) with bullish sentiments. Confident Investing Starts Here: Exact Sciences (EXAS) In a report issued on June 2, Brandon Couillard from Wells Fargo maintained a Buy rating on Exact Sciences, with a price target of $68.00. The company's shares closed last Tuesday at $54.84. According to Couillard is a 5-star analyst with an average return of 14.1% and a 59.5% success rate. Couillard covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, Bio-Rad Laboratories, and Myriad Genetics. Exact Sciences has an analyst consensus of Strong Buy, with a price target consensus of $69.94. In a report issued on June 2, Daina Graybosch from Leerink Partners maintained a Buy rating on Arcus Biosciences, with a price target of $46.00. The company's shares closed last Tuesday at $10.03. According to Graybosch has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -15.0% and a 33.3% success rate. Graybosch covers the Healthcare sector, focusing on stocks such as Turnstone Biologics Corp., Werewolf Therapeutics, and Century Therapeutics. Currently, the analyst consensus on Arcus Biosciences is a Strong Buy with an average price target of $27.88, representing a 203.4% upside. In a report issued on May 23, Barclays also maintained a Buy rating on the stock with a $14.00 price target.
